Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human papillomavirus bivalent (types 16, 18) vaccine
- Development stage
- Phase 4
- Lead developer
- Xiamen Innovax Biotech
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Cecolin is a prophylactic bivalent vaccine indicated for the prevention of diseases caused by oncogenic human papillomavirus (HPV) types 16 and/or 18. It is approved for use in women aged 9 to 45 years. The active ingredients are recombinant L1 capsid proteins of HPV type-16 and type-18, each self-assembled into virus-like particles (VLPs), produced using *Escherichia coli* expression technology. Cecolin works by inducing an immune response that prevents infection with HPV types most commonly associated with cervical cancer and its precursors. It does not treat existing infections or lesions but is highly effective at preventing new infections from these high-risk HPV types. The primary developer and manufacturer is Xiamen Innovax Biotech Co., Ltd., in collaboration with Xiamen University[2][3][5][8].
- Brand names
- Cecolin
- Other names
- CecolinHPV vaccine (bivalent, types 16 and 18)recombinant human papillomavirus bivalent (types 16, 18) vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)HPV16 (Human papillomavirus type 16)HPV18 L1
Beyond the preview
Go deeper on recombinant human papillomavirus bivalent (types 16, 18) vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human papillomavirus bivalent (types 16, 18) vaccine.